Shorter courses of proton therapy can be just as effective as full courses prostate cancer

(University of Pennsylvania School of Medicine) Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments and is safe for patients.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Technical advances have made it possible to create highly conformal dose distributions using photon-based radiotherapy, prompting interest in hypofractionated radiotherapy. Prostate cancer shows higher fractionation sensitivity and a lower α/β ratio than healthy tissue; thus, the rationale is to use higher doses per fraction compared with conventional fractionation [1–3]. Randomized studies have shown that moderate hypofractionation was not inferior to conventional fractions [4–6], but they have not demonstrated the concept of b iological dose escalation i.e.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
ConclusionRITI can be induced in patients with NSCLC through upregulated IgG and/or IgM. RITI response was not associated with proton versus photon therapy or with clinical outcomes in this small cohort and should be examined in a larger cohort in future studies.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
This study was performed to determine the clinical and patient-reported outcomes for patients with PC treated with HFPT.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
PMID: 31166085 [PubMed - as supplied by publisher]
Source: Journal of Applied Clinical Medical Physics - Category: Physics Authors: Tags: J Appl Clin Med Phys Source Type: research
Abstract The purpose of this study was the evaluation of the impact of a variable relative biological effectiveness (RBE) compared to a constant RBE value of 1.1 in proton therapy prostate trials due to uncertainties in α/β ratio.
 Twenty patients receiving passive scattered proton therapy (PSPT) and fifteen patients receiving intensity modulated proton therapy (IMPT) were compared to twenty patients treated with 7-field intensity modulated photon therapy (IMRT). For proton beam therapy (PBT), the RBE was estimated using two different RBE models. Tumor control probabilities (TCP) and n...
Source: Physics in Medicine and Biology - Category: Physics Authors: Tags: Phys Med Biol Source Type: research
CONCLUSIONS: Patient-reported pretreatment sexual function and comorbidities enables stratification and prediction of erectile function. EPIC subset questions with baseline comorbidities may potentially serve as a quick and practical clinical tool for predicting sexual survivorship. PMID: 31005217 [PubMed - in process]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Authors: Nichols RC, Morris CG, Bryant C, Hoppe BS, Henderson RH, Mendenhall WM, Li Z, Costa JA, Williams CR, Mendenhall NP Abstract Studies demonstrate a decline of ∼10% in serum testosterone (ST) level after X-ray radiotherapy for prostate cancer. We evaluated changes in ST for patients with low- and intermediate-risk prostate cancer receiving 70-82Gy(RBE) using passive-scatter proton therapy (PT). ST was checked at baseline (n = 358) and at 60+ months after PT (n = 166). The median baseline ST was 363.3 ng/dl (range, 82.0-974.0). The median ST 5 years after PT was 39...
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
Sexual survivorship after primary treatment for prostate cancer is an important quality-of-life (QOL) metric for measuring satisfactory outcomes. Among patients surveyed, post-treatment sexual function rates highly among factors when considering treatment decisions [1]. Several high-impact studies have looked at QOL survivorship among men who are impotent or on androgen deprivation therapy (ADT) before treatment [2 –8]; few studies, such as the Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment (PROSTQA) Consortium, provide a model for predicting post-treatment patient-reported QOL [6,7,9].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
This study was an exploratory analysis to investigate the secondary end...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Abstract Men diagnosed with localized prostate cancer have many curative treatment options including several different radiotherapeutic approaches. Proton radiation is one such radiation treatment modality and, due to its unique physical properties, offers the appealing potential of reduced side effects without sacrificing cancer control. In this review, we examine the intriguing dosimetric rationale and theoretical benefit of proton radiation for prostate cancer and highlight the results of preclinical modeling studies. We then discuss the current state of the clinical evidence for proton efficacy and toxicity, d...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | International Medicine & Public Health | Prostate Cancer | Proton Therapy | University of Pennsylvania